Insider Buying: TELA Bio, Inc. (NASDAQ: TELA) Insider buys 5,000 shares

TELA Bio, Inc. (NASDAQ: TELA – Get a rating) insider Ew Healthcare Partners Fund 2, bought 5,000 shares in a trade that took place on Wednesday, May 25. The shares were purchased at an average price of $6.87 per share, for a total transaction of $34,350.00. Following the completion of the purchase, the insider now directly owns 3,445,709 shares of the company, valued at $23,672,020.83. The transaction was disclosed in a legal filing with the SEC, available at this link.

Ew Healthcare Partners Fund 2, also recently completed the following transaction(s):

  • On Friday May 27, Ew Healthcare Partners Fund 2 acquired 5,000 shares of TELA Bio stock. The stock was purchased at an average price of $7.43 per share, for a total transaction of $37,150.00.
  • On Monday, May 23, Ew Healthcare Partners Fund 2 purchased 5,000 shares of TELA Bio. The shares were acquired at an average cost of $8.53 per share, with a total value of $42,650.00.
  • On Friday, May 20, Ew Healthcare Partners Fund 2 purchased 5,000 shares of TELA Bio. The shares were acquired at an average cost of $8.79 per share, with a total value of $43,950.00.
  • On Wednesday, May 18, Ew Healthcare Partners Fund 2 purchased 5,000 shares of TELA Bio. The shares were acquired at an average cost of $8.96 per share, with a total value of $44,800.00.
  • On Monday, May 16, Ew Healthcare Partners Fund 2 purchased 5,000 shares of TELA Bio. The shares were acquired at an average cost of $8.61 per share, with a total value of $43,050.00.
  • On Friday May 13, Ew Healthcare Partners Fund 2 purchased 5,000 shares of TELA Bio. The shares were acquired at an average cost of $8.48 per share, with a total value of $42,400.00.
  • On Wednesday May 11, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average price of $8.82 per share, for a total transaction of $44,100.00.
  • On Monday, May 9, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average price of $9.38 per share, for a total transaction of $46,900.00.
  • On Friday May 6, Ew Healthcare Partners Fund 2 acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average price of $9.55 per share, for a total transaction of $47,750.00.
  • On Wednesday, May 4, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average price of $9.53 per share, for a total transaction of $47,650.00.
(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Shares of NASDAQ:TELA traded at $0.36 in Friday’s midday session, hitting $7.36. The company had a trading volume of 48,698 shares, compared to an average volume of 34,878. TELA Bio, Inc. has a 12-month low of $6.32 and a 12-month high of $16.53. The company has a current ratio of 4.10, a quick ratio of 3.26 and a debt ratio of 3.15. The stock has a market capitalization of $107.15 million, a price-earnings ratio of -2.97 and a beta of 1.57. The company has a fifty-day simple moving average of $9.82 and a 200-day simple moving average of $11.44.

TELA Bio (NASDAQ: TELA – Get a rating) last released its quarterly results on Tuesday, May 10. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.25). TELA Bio had a negative return on equity of 155.13% and a negative net margin of 113.15%. In the same period a year earlier, the company had earned earnings per share ($0.56). Equity analysts expect TELA Bio, Inc. to post EPS of -2.47 for the current fiscal year.

A number of brokerages have commented on TELA. Zacks Investment Research upgraded TELA Bio from a “sell” rating to a “hold” rating in a research report on Tuesday. JMP Securities reiterated a “buy” rating and issued a $22.00 price target on TELA Bio shares in a research report on Tuesday, March 22.

Several large investors have recently bought and sold shares of TELA. Geode Capital Management LLC increased its stake in TELA Bio by 1.3% during the third quarter. Geode Capital Management LLC now owns 64,923 shares of the company worth $886,000 after acquiring 824 additional shares in the last quarter. BlackRock Inc. increased its stake in TELA Bio by 4.1% during the fourth quarter. BlackRock Inc. now owns 22,392 shares of the company worth $287,000 after acquiring 886 additional shares in the last quarter. Pentwater Capital Management LP increased its stake in TELA Bio by 0.3% during the fourth quarter. Pentwater Capital Management LP now owns 312,238 shares of the company worth $3,997,000 after acquiring 1,022 additional shares last quarter. Bank of America Corp DE increased its stake in TELA Bio by 16.6% during the second quarter. Bank of America Corp DE now owns 7,682 shares of the company worth $124,000 after acquiring 1,093 additional shares in the last quarter. Finally, State Street Corp increased its stake in TELA Bio by 9.1% during the first quarter. State Street Corp now owns 26,065 shares of the company worth $303,000 after acquiring 2,167 additional shares in the last quarter.

About TELA Bio (Get a rating)

TELA Bio, Inc., a commercial-stage medical technology company, is focused on providing soft tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of patient anatomy. It offers a portfolio of OviTex (OviTex) tissue-enhanced matrix products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix to address unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile ovine rumen-derived reinforced tissue matrix with polypropylene fiber for use in laparoscopic surgery and robot-assisted surgical repairs of hernias.

See also

Insider buying and selling by quarter for TELA Bio (NASDAQ:TELA)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in TELA Bio right now?

Before you consider TELA Bio, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and TELA Bio wasn’t on the list.

While TELA Bio currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Comments are closed.